ASH 2014: Amgen/Onyx's Kyprolis improves survival, quality of life
This article was originally published in Scrip
Executive Summary
Amgen's Onyx Pharmaceuticals subsidiary reported on 6 December that giving Kyprolis (carfilzomib) to newly-diagnosed multiple myeloma patients on top of Celgene's Revlimid (lenalidomide) plus dexamethasone reduced the risk of death by 21% and improved quality of life.